<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053937</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269598</org_study_id>
    <secondary_id>NCI-03-C-0058A</secondary_id>
    <nct_id>NCT00053937</nct_id>
    <nct_alias>NCT00050453</nct_alias>
  </id_info>
  <brief_title>Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas</brief_title>
  <official_title>Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. Pirfenidone may slow the growth or prevent further&#xD;
      development of plexiform neurofibromas.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients&#xD;
      who have neurofibromatosis type 1 and plexiform neurofibroma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose or &quot;comparable dose&quot; of pirfenidone in pediatric&#xD;
           patients with neurofibromatosis type 1 and inoperable, symptomatic plexiform&#xD;
           neurofibromas.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, if this drug could be beneficial for pediatric patients with&#xD;
           refractory solid tumors.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive oral pirfenidone three times daily on days 1-28. Courses repeat every 28&#xD;
      days for up to 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of pirfenidone until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, before course 4, and then after every 6 courses.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Neurofibromatosis Type 1</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirfenidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of neurofibromatosis type 1 (NF1) AND&#xD;
&#xD;
          -  Plexiform neurofibromas&#xD;
&#xD;
               -  Neurofibromas that have grown along the length of a nerve and may involve&#xD;
                  multiple fascicles and branches (spinal neurofibromas involve 2 or more levels&#xD;
                  with connection between the levels or extending laterally along the nerve)&#xD;
&#xD;
               -  Potential to cause significant morbidity such as:&#xD;
&#xD;
                    -  Head and neck lesions that could compromise airway or great vessels&#xD;
&#xD;
                    -  Brachial or lumbar plexus lesions that could cause nerve compression and&#xD;
                       loss of function&#xD;
&#xD;
                    -  Lesions that could result in major deformity (e.g., orbital lesions) or&#xD;
                       significant cosmetic problems&#xD;
&#xD;
                    -  Lesions of the extremity that cause limb hypertrophy or loss of function&#xD;
&#xD;
                    -  Painful lesions&#xD;
&#xD;
          -  Meets at least 1 other diagnostic criteria for NF1&#xD;
&#xD;
               -  6 or more cafe-au-lait spots (at least 0.5 cm in prepubertal patients or at least&#xD;
                  1.5 cm in postpubertal patients)&#xD;
&#xD;
               -  Freckling in the axilla or groin&#xD;
&#xD;
               -  Optic glioma&#xD;
&#xD;
               -  2 or more Lisch nodules&#xD;
&#xD;
               -  Distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning&#xD;
                  of long bone cortex)&#xD;
&#xD;
               -  First-degree relative with NF1&#xD;
&#xD;
          -  Measurable plexiform neurofibromas&#xD;
&#xD;
               -  At least 3 cm in 1 dimension&#xD;
&#xD;
               -  Tumor resection not feasible&#xD;
&#xD;
          -  No history of malignant peripheral nerve sheath tumor or other cancer&#xD;
&#xD;
          -  No evidence of an active optic glioma requiring chemotherapy or radiotherapy&#xD;
&#xD;
          -  No malignant glioma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% (over 10 years of age)&#xD;
&#xD;
          -  Lansky 50-100% (10 years and under)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGPT no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  No clinically significant hepatic dysfunction that would preclude study participation&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal for age OR&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant cardiac dysfunction that would preclude study participation&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant pulmonary dysfunction that would preclude study&#xD;
             participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
&#xD;
          -  Must be able to take pirfenidone orally&#xD;
&#xD;
          -  No serious infections&#xD;
&#xD;
          -  No clinically significant unrelated systemic illness or organ dysfunction that would&#xD;
             preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 30 days since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 30 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy directed at the tumor&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 30 days since prior hormonal therapy directed at the tumor&#xD;
&#xD;
          -  No concurrent hormonal therapy directed at the tumor&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 90 days since prior radiotherapy to the site of the plexiform neurofibroma&#xD;
&#xD;
          -  No concurrent radiotherapy directed at the tumor&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No prior pirfenidone&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte C. Widemann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center - Singer Division</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital at State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>plexiform neurofibroma</keyword>
  <keyword>neurofibromatosis type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

